SDC1 and Miyoshi myopathy: To date, targeting CD138 for treatment of MM was clinically evaluated using indatuximab ravtansine (BT062), an anti-CD138 mAb (BB4) drug conjugate (ADC) specifically delivering a cytotoxic maytansine derivative to MM cells25.